TIGIT, a major immune checkpoint molecule, is expressed on the surface of T cells and natural killer (NK) cells. In 2002, researchers from Genentech first discovered this gene, which exhibited specific expression in T cells and NK cells. Subsequently, TIGIT made its debut in 2009 in Nature Immunology, where it was identified to possess an immunoglobulin-like (IgV) domain and an immunoreceptor tyrosine-based inhibition motif (ITIM). Scientists thus named it TIGIT (T-cell immunoreceptor with Ig

On July 10, BeiGene and DualityBio have announced an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational ADC therapy for patients with select solid tumors. DualityBio will continue preclinical research activities and support Investigational New Drug filing while BeiGene will hold global clinical, manufacturing, and commercial rights upon exercising its option. Under the terms of the agreement, DualityBio will receive an upfront

At the beginning of the year, GSK announced its decision to discontinue investments in the field of cell and gene therapies and shift its focus to small nucleic acid drugs. This news immediately brought small nucleic acid drugs into the spotlight, capturing people's attention and enthusiasm. In fact, in December 2022, GSK entered into a partnership with nucleic acid therapeutics company Wave Life Sciences, with GSK providing a total investment of $3.3 billion to support the development of smal

PARP7 functions by catalyzing the transfer of a single ADP-ribose unit onto substrates, altering their functionality. As a negative regulator of nucleic acid sensing in tumor cells, inhibiting PARP7 has demonstrated remarkable effects in restoring the response of nucleic acids to the type I interferon (IFN) signaling pathway in tumor models. This restoration of signaling not only directly inhibits cell proliferation but also activates the immune system, contributing to tumor regression. The pr

In April 2023, at the American Association for Cancer Research (AACR) annual meeting, Moderna and Merck announced detailed information about the phase 2b clinical trial of mRNA-4157 in combination with Keytruda for the treatment of melanoma. The study demonstrated that in patients with advanced melanoma, approximately 79% of patients who received Moderna's mRNA-based cancer vaccine in combination with Merck's immune checkpoint inhibitor Keytruda remained recurrence-free after 18 months, compar

Study results of novel drug-eluting technology highlight potential durability of TAR-200 in patient population with high unmet need CHICAGO, April 30, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from the open-label Phase 2 SunRISe-1 study evaluating the efficacy and safety of TAR-200 monotherapy (a novel investigational intravesical drug delivery system) and cetrelimab monotherapy (an investigational anti-PD-1 monoclonal antibody administere

In January 2025, China’s innovative pharmaceutical sector continues to make its mark on the global stage. The collaboration between Innovent Biologics and Roche marks the international launch of IBI3009, an antibody-drug conjugate (ADC) targeting small cell lung cancer (SCLC). Meanwhile, the partnership between Duality Biologics and Avenzo Therapeutics concerning the EGFR/HER3 bispecific ADC, DB-1418/AVZO-1418, further demonstrates China’s progress in developing complex and efficient cancer ther

First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 2025 New 12-month data on the first three adult OPGx-LCA5 patients to be presented at a major medical conference in Q2 2025 FDA meeting scheduled in March 2025 to discuss Phase 3 trial design and registrational endpoints for OPGx-LCA5 Feb. 18, 2025 -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the tr

Trial decision follows unanticipated events of elevated unconjugated bilirubin levels Company advancing multiple next-generation PTH1R agonists with distinct and unrelated chemical structures relative to SEP-786 Feb. 18, 2025 -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery, today announced its decision to discontinue the Phase 1 single- and multiple-ascending dose (SAD/MAD) clinical trial of SEP-786 in healthy volunteers. SEP-

Data reinforce unique clinical advantages of sotagliflozin Published study is aligned with research presented in December 2024 at the American Society of Hematology showing clinical benefits of sotagliflozin compared to empagliflozin Feb. 18, 2025 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced The Lancet Diabetes & Endocrinology has published a research paper analyzing the ability of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, to reduce the risks of life-threatening cardio